Bevacizumab-induced small bowel perforation in a patient with breast cancer without intraabdominal metastases
Tóm tắt
A 53-years-old woman presented with sudden abdominal pain. One year before, she was diagnosed an inflammatory ductal carcinoma of the left breast (T3N0M0) and received 6 cycles of epirubicin and cyclophosphamide followed by 9 cycles of paclitaxel. A radical left mastectomy with lymphadenectomy was performed. On histopathology, the invasive ductal carcinoma was poorly differentiated, histological grade III without lymphovascular emboli, expressing E-cadherin, with negative hormone receptors status and no HER-2 overexpression. The final staging after chemotherapy was pT3N1M0, necessitating an adjuvant radiotherapy. Four months postoperatively, a CT-scan revealed liver and lung metastases and chemotherapy combining gemcitabine, oxaliplatin and bevacizumab was started for 13 days when she suddenly developed severe abdominal pain. A CT-scan showed a pneumoperitoneum. She had a median laparotomy confirming the diagnosis of peritonitis by digestive perforation without ovarian, uterine, lymphatic, or peritoneal carcinomatosis. Assessment of the totality of the gastrointestinal tract showed two distinct punched out perforations of the small bowel, without macroscopic signs of tumor or metastases: one on the jejunum at 50 cm from the Treitz and the second at 10 cm of the end of the ileum. Small bowel resection with jejunojejunostomy and a lateral ileostomy were performed. Regarding the macroscopical pathological findings, the mucosa showed an ulceration measuring of 1 cm without tumor. On microscopy we found a tranparietal neoplastic infiltration. Vessels were morphologically normal with tumoral cells’ morphology and architecture identical to the primary breast carcinoma. Chemotherapy was not reintroduced after surgery and the patient died on the 57th postoperative day.
Tài liệu tham khảo
Hapani S, Chu D, Wu S (2009) Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 10:534–536
Miller K, Wang M, Gralow J et al (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 26:2666–2676
Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 23:2335–2342
Jemal A, Siegel R, Ward E et al (2009) Cancer statistics, 2009. CA Cancer J Clin 4:225–249
Jain S, Fisher C, Smith P, Millis RR, Rubens RD (1993) Patterns of metastatic breast cancer in relation to histological type. Eur J Cancer 15:2155–2157
Chang SF, Burrell MI, Brand MH, Garsten JJ (1978) The protean gastrointestinal manifestations of metastatic breast carcinoma. Radiology 3:611–617
Cifuentes N, Pickren JW (1979) Metastases from carcinoma of mammary gland: an autopsy study. J Surg Oncol 3:193–205
McLemore EC, Pockaj BA, Reynolds C et al (2005) Breast cancer: presentation and intervention in women with gastrointestinal metastasis and carcinomatosis. Ann Surg Oncol 11:886–894
Asch MJ, Wiedel PD, Habif DV (1968) Gastrointestinal metastases from crcinoma of the breast. Autopsy study and 18 cases requiring operative intervention. Arch Surg 5:840–843
Cornu-Labat G, Ghani A, Smith DJ, McDonald AD, Kasirajan K (1998) Small-bowel perforation secondary to metastatic carcinoma of the breast. Am Surg 4:312
Gressett SM, Shah SR (2009) Intricacies of bevacizumab-induced toxicities and their management. Ann Pharmacother 3:490–501
Scott LJ (2007) Bevacizumab: in first-line treatment of metastatic breast cancer. Drugs 12:1793–1799
Han ES, Monk BJ (2007) Bevacizumab in the treatment of ovarian cancer. Expert Rev Anticancer Ther 10:1339–1345
Mir O, Mouthon L, Alexandre J et al (2007) Bevacizumab-induced cardiovascular events: a consequence of cholesterol emboli syndrome? J Natl Cancer Inst 1:85–86